Literature DB >> 9461231

Low-density lipoprotein oxidation and vitamins E and C in sustained and white-coat hypertension.

S D Pierdomenico1, F Costantini, A Bucci, D De Cesare, F Cuccurullo, A Mezzetti.   

Abstract

Low-density lipoprotein oxidation and antioxidant vitamins E and C were investigated in white-coat hypertension in comparison with sustained hypertension and normotension. We selected 21 sustained hypertensive subjects, 21 white-coat hypertensive subjects, and 21 normotensive subjects matched for gender, age, and body mass index. White-coat hypertension was defined as clinical hypertension and daytime ambulatory blood pressure <139/90 (subjects were also reclassified using 134/90 and 135/85 mm Hg as cutoff points for daytime blood pressure). Blood samples were drawn for lipid profile determination, assessment of fluorescent products of lipid peroxidation in native LDL, evaluation of susceptibility to LDL oxidation in vitro (lag phase and propagation rate), and determination of LDL vitamin E and plasma vitamins E and C contents. Compared with sustained hypertensive subjects, white-coat hypertensives had significantly lower fluorescent products of lipid peroxidation (15.4+/-3.4 versus 10.2+/-3 units of relative fluorescence/mg LDL protein, P<.05), longer lag phase (54+/-10 versus 88+/-10 minutes, P<.05), lower propagation rate (8.2+/-2.5 versus 5.95+/-2.1 nmol diene/min per mg LDL cholesterol, P<.05), higher LDL vitamin E content (8.3+/-1.1 versus 10.1+/-1.8 nmol/mg LDL cholesterol, P<.05), and plasma vitamin C content (40+/-13 versus 57+9 micromol/L, P<. 05). No significant difference was observed between white-coat hypertensive and normotensive subjects. The results did not change after reclassification of subjects. Our data show that white-coat hypertensive subjects do not show an enhanced propensity to LDL oxidation or reduction in antioxidant vitamins. Given the role of LDL oxidation in the development of atherosclerosis and that of vitamin E and C in protecting against it, these findings suggest that white-coat hypertension per se carries a low atherogenic risk.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9461231     DOI: 10.1161/01.hyp.31.2.621

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  7 in total

Review 1.  Should antioxidant status be considered in interventional trials with antioxidants?

Authors:  F Violi; L Loffredo; L Musella; A Marcoccia
Journal:  Heart       Date:  2004-06       Impact factor: 5.994

Review 2.  The planetary biology of ascorbate and uric acid and their relationship with the epidemic of obesity and cardiovascular disease.

Authors:  Richard J Johnson; Eric A Gaucher; Yuri Y Sautin; George N Henderson; Alex J Angerhofer; Steven A Benner
Journal:  Med Hypotheses       Date:  2008-03-10       Impact factor: 1.538

3.  Dietary vitamin E and C supplementation prevents fructose induced hypertension in rats.

Authors:  S Vasdev; V Gill; S Parai; L Longerich; V Gadag
Journal:  Mol Cell Biochem       Date:  2002-12       Impact factor: 3.396

4.  Dietary vitamin C supplementation lowers blood pressure in spontaneously hypertensive rats.

Authors:  S Vasdev; C A Ford; S Parai; L Longerich; V Gadag
Journal:  Mol Cell Biochem       Date:  2001-02       Impact factor: 3.396

5.  Single- or double-blind treatment With Balsamodendron mukul and nifedipine in hypertensive patients.

Authors:  Jayabal Panneerselvam; Ganapathy Sambandam; Namasivayam Nalini
Journal:  J Clin Hypertens (Greenwich)       Date:  2005-06       Impact factor: 3.738

6.  Association between Serum Vitamin C and the Blood Pressure: A Systematic Review and Meta-Analysis of Observational Studies.

Authors:  Li Ran; Wenli Zhao; Xiaodong Tan; Hongwu Wang; Kaito Mizuno; Ken Takagi; Ye Zhao; Huaien Bu
Journal:  Cardiovasc Ther       Date:  2020-04-29       Impact factor: 3.023

7.  The impact of protein oxidation on sustained and white coat hypertension.

Authors:  Erkan Yıldırım; Emrah İpek; Işıl Bavunoğlu; Nilgün Yıldırım; Mahir Cengiz; Serap Yavuzer; Hakan Yavuzer; Hayriye Erman; Hafize Uzun
Journal:  Anatol J Cardiol       Date:  2016-09-28       Impact factor: 1.596

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.